Powerful
ARB + diuretic
Take control with a
Powerful ARB + diuretic
EDARBYCLOR® (azilsartan medoxomil/chlorthalidone) is 2 medicines in 1 to help you get to goal. If one medication is not enough or if you need more than one medicine to reach your blood pressure goal, EDARBYCLOR may be a good fit for you.1 EDARBYCLOR combines the same active ingredient in EDARBI®, azilsartan medoxomil, with the diuretic (“water pill”) chlorthalidone. The ARB in EDARBYCLOR works by relaxing blood vessels, and the diuretic works in the kidneys to help flush excess water and salt (sodium) from the body. Together, these 2 medicines help to lower blood pressure.1
I’m not just 169/96.
I’m Glenn.
EDARBYCLOR outperforms Similar
Medication in Studies.2*
When scientists compared EDARBYCLOR 40/25 mg with Benicar HCT® (olmesartan medoxomil-hydrochlorothiazide) 40/25 mg for 12 weeks, they found that EDARBYCLOR lowered blood pressure better.2
14.5% greater reduction
than Benicar HCT
Proper medical treatment and control has been shown to lower the risk of dying from heart-related problems such as heart attack and stroke.4†
*Based on clinical trial data vs Benicar HCT® (olmesartan medoxomil-hydrochlorothiazide).2
† CV risk reduction with EDARBI and EDARBYCLOR has not been established.
EDARBYCLOR Is Effective for
African American Patients1,5
From a subgroup analysis of the same clinical trial, another benefit of EDARBYCLOR was discovered: It is especially effective at lowering blood pressure among African American patients with high blood pressure.5
18% greater SBP reduction
than Benicar HCT5*
This is important because common treatments such as renin angiotensin system (RAS) inhibitors are generally less effective in low-renin populations, including African Americans.6 EDARBYCLOR provides a choice for these populations.5
*Based on clinical trial data vs Benicar HCT, comparing 40/25 dose of EDARBYCLOR to 40/25 mg dose of Benicar HCT among African American participants.5
and Tolerability
Your doctor may monitor the potassium and creatinine levels in your blood while you’re taking EDARBYCLOR.1
EDARBYCLOR may cause serious side effects, including low blood pressure (hypotension), which may cause dizziness or feeling faint.1
Vomiting and diarrhea, a low-salt diet, sweating a lot, or not drinking enough fluids can also lead to low blood pressure.1
If you are taking EDARBYCLOR and experience side effects that concern you, call your doctor for medical advice. You are encouraged to report side effects of prescription drugs to Azurity Pharmaceuticals, Inc. Medical Information at 1-866-516-4950 or to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.
Recommended Dosing
Dosing
EDARBYCLOR is a once-daily oral medication that can help you achieve your blood pressure goals.1
- May be administered with or without food.
- May be administered with other antihypertensive agents.
- Dose may be increased to 40/25 mg after 2 to 4 weeks as needed to achieve BP goals.
- Correct volume depletion in patients prior to use.
- Doses above maximum are probably not useful.
EDARBI®
(azilsartan
medoxomil)
Take control with a powerful ARB8
- 1. Edarbyclor [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc; 2022.
- 2. Cushman WC, Bakris GL, White WB, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012;60(2):310-318.
- 3. Stamler R. Implications of the INTERSALT study. Hypertension. 1991;17(1 Suppl):I16-20.
- 4. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324.
- 5. Ferdinand KC, Bakris GL, Cushman WC, et al. Comparison of effectiveness of azilsartan medoxomil and olmesartan in Blacks versus whites with systemic hypertension. Am J Cardiol. 2018;122(9):1496-1505.
- 6. Williams SF, Nicholas SB, Vaziri ND, Norris KC. African Americans, hypertension and the renin angiotensin system. World J Cardiol. 2014;6(9):878-889.
- 7. Edarbi [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc; 2024.